AVALO THERAPEUTICS, INC. Income (Loss) Attributable to Parent, before Tax
AVALO THERAPEUTICS, INC. (AVTX) reported Income (Loss) Attributable to Parent, before Tax of -$41.63 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossAttributableToParent · last filed 2023-03-29
- AVALO THERAPEUTICS, INC. income (loss) attributable to parent, before tax for fiscal 2022 was -$41.63M.
- AVALO THERAPEUTICS, INC. income (loss) attributable to parent, before tax for fiscal 2021 was -$84.55M.
- AVALO THERAPEUTICS, INC. income (loss) attributable to parent, before tax for fiscal 2020 was -$67.18M.
- AVALO THERAPEUTICS, INC. income (loss) attributable to parent, before tax for fiscal 2019 was -$15.99M.
| Period end | Income (Loss) Attributable to Parent, before Tax 12 month | Income (Loss) Attributable to Parent, before Tax 12 month as first filed |
|---|---|---|
| 2022-12-31 | -$41.63M 10-K · filed 2023-03-29 | |
| 2021-12-31 | -$84.55M 10-K · filed 2023-03-29 | |
| 2020-12-31 | -$67.18M 10-K · filed 2022-03-02 | -$67.18M 10-K · filed 2021-03-08 |
| 2019-12-31 | -$15.99M 10-K · filed 2021-03-08 | |
| 2018-12-31 | -$35.32M 10-K · filed 2020-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |